Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • AUD/USD

    0.6491
    -0.0045 (-0.69%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    81.95
    +0.60 (+0.74%)
     
  • GOLD

    2,218.70
    +6.00 (+0.27%)
     
  • Bitcoin AUD

    108,614.31
    +704.95 (+0.65%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.